• CEL-SCI signed a strategic agreement with Saudi Amarox at BIO 2026 to support the planned launch and commercialization of Multikine in Saudi Arabia.
• Scope could extend to other regional markets, subject to regulatory approvals.
• Partnership targets Saudi Arabia’s push to expand access to innovative oncology treatments under its Vision 2030 healthcare modernization program.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CEL-SCI Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20260624665046) on June 24, 2026, and is solely responsible for the information contained therein.